RE:Safety is more important...This is completely baseless speculation. Theralase could not have been more clear.
"...no patients have been diagnosed with a Serious Adverse Event ("SAE") directly related to the Study Drug or Study" Some variation of this statement is in every news release stretching back to tbe beginning of trial updates.
But you are claiming a major trial delay based on nothing but your news starved imagination.
wildbird1 wrote: In Aug 2023, the FDA asked TLT for extra data clarifications. We all did assume(including me) that it was the 450 days efficacy data that the FDA wanted.
After reading the last update March 27,2024 ... there is a very big chance that there was a more justifiable reason for the FDA asking TLT for more data clarifications.
In the Aug 2023 PressRelease TLT said '' For 60 patients treated in study11, there have been 9 '' serious adverse events'' reported.
9/60 = 15% of patients treated.
In the last update March 27,2024 TLT said'' For 64 patients treated, there have been 13 ''serious adverse events''.
13/64 = 22% of patients treated.
In Aug 2023 the FDA must have noticed a steady increase in the '' serious adverse events'' data.
The increase although it was not alarming, it was worth asking TLT to double check the ''serious adverse events'' data''.
The FDA asking TLT to double check the ''serious adverse events'' data is very legitimate, after all the appointmnent to the Data Safety Monitoring Board(DSMB) are made by the study11 sponsor(TLT is financing the DSMB).
In short...
There is nothing of grave concern here, the FDA is simply doing its job by asking TLT to double check its own ''serious adverse events'' data to make sure that the increase is not related to the study11 treatment drug(Ruvidar).
Question?
Why is the ''serious adverse events'' % increasing?
The answer could be in the the last Corporate Presentation(03,19,2024) page 14...under '' previous BCG therapy treatments''.
It is said '' 21% of patients have received over 19 BCG treatments''.
A patient that has received over 19 BCG treatments is usually an older patients who is in really bad shape and also a patient who is almost untreatable.
Note: 21% of patients with over 19 BCG treatments, is very close to the 22% of ''serious adverse events''( coincidence maybe not).
You have to give credit to TLT for treating older patients that nobody else want to treat,TLT could have simply placed these patients on its exclusion criterias list, and the CR% would have increased accordingly.
Now the good news...
As we speak TLT must have double checked most of the CSS(Clinical Study Sites) data and came to the conclusion that the data submitted to the FDA on '' serious adverse events'' were accurate and all ''serious adverse events'' were unrelated to the study11 drug(Ruvidar).
Why???
In Aug 2023 the hiring of new patients came almost to a complete stop, lately Dr.Jewett came on board specifically to help increasing enrollement of new patients, indicating that everything is back on track.
Extra notes;
1) If something goes wrong with safety(serious adverse events) after the BTD approval, it is the FDA that will take the blame for the early BTD approval.
2) Checking the 450 days efficacy data is simply a logical step not related to the BTD approval. The 450 days efficacy data will be very important for the phase11 final clinical data(2026), and when TLT will try to become the standard of care.
3) My post is strickly based on the fact that for me, safety is more important than efficacy when the FDA give early BTD approval.
Why???
-A low efficacy doesn't kill a patient, it simply doesn't cure the patient.
-But ''serious adverse events'' could kill a patient if left unchecked".
For now, up to 40% efficacy and 100% safe.
BTD approval is in the bag.
(you already knew that).